


## Thalidomide-O-amido-C6-NH<sub>2</sub>

Cat. No.:	HY-112618
CAS No.:	1950635-13-8
Molecular Formula:	C <sub>21</sub> H <sub>26</sub> N <sub>4</sub> O <sub>6</sub>
Molecular Weight:	430.45
Target:	E3 Ligase Ligand-Linker Conjugates
Pathway:	PROTAC
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

Description	Thalidomide-O-amido-C6-NH <sub>2</sub> (Cereblon Ligand-Linker Conjugates 11), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs <sup>[1]</sup> .
IC <sub>50</sub> & Target	Cereblon
In Vitro	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Bradner J, et al. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses. WO 2017024318 A1.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA